În contextul dificultăților de abordare terapeutică a pacienților cu dermatită atopică, vă prezentăm mai jos o trecere în revistă a unor studii contemporane, având drept obiectiv îmbunătățirea managementului clinic, de diagnostic și tratament al acestei afecțiuni.

  • Zabalafin Hydrogel Significantly Improves Itch in Phase 2a Trial for AD

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/zabalafin-hydrogel-significantly-improves-itch-in-phase-2a-trial-for-ad

  • Apogee Announces Positive Phase 1 Interim Data for APG777 in Atopic Dermatitis, Inflammatory Diseases

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/apogee-announces-positive-phase-1-interim-data-for-apg777-in-atopic-dermatitis-inflammatory-diseases

  • FDA Approves Tralokinumab-ldrm for Atopic Dermatitis in Patients Ages 12-17

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/fda-approves-tralokinumab-ldrm-for-atopic-dermatitis-in-patients-ages-12-17

  • Association Found Between Atopic Dermatitis and Altered Oral Microbiome

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/association-found-between-atopic-dermatitis-and-altered-oral-microbiome

  • FDA Accepts sNDA for Arcutis’ Roflumilast Cream 0.15% for Atopic Dermatitis, Sets July 2024 PDUFA Date

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/fda-accepts-snda-for-arcutis-roflumilast-cream-0-15-for-atopic-dermatitis-sets-july-2024-pdufa-date

  • Incyte Announces Expanded TRuE-AD3 Data at EADV

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/incyte-announces-expanded-true-ad3-data-at-eadv

  • ADvantage, ADvocate Studies Support Clinical Improvements of AD With Lebrikizumab

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/advantage-advocate-studies-support-clinical-improvements-of-ad-with-lebrikizumab

  • Amlitelimab Significantly Improves Average EASI Scores in Phase 2b AD Study

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/amlitelimab-significantly-improves-average-easi-scores-in-phase-2b-ad-study

  • Eric Simpson, MD, Discusses Recently Announced EADV Data On Tapinarof Cream for AD Down to 2 Years

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/eric-simpson-md-discusses-recently-announced-eadv-data-on-tapinarof-cream-for-ad-down-to-2-years

  • New Phase 3 Data on Long-Term Efficacy of Upadacitinib in Atopic Dermatitis Presented at EADV

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/new-phase-3-data-on-long-term-efficacy-of-upadacitinib-in-atopic-dermatitis-presented-at-eadv

  • Gut Microbiome Has Significant Impact on Atopic Dermatitis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/gut-microbiome-has-significant-impact-on-atopic-dermatitis

  • Advances in Diagnosing and Treating Atopic Dermatitis in the Elderly

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/advances-in-diagnosing-and-treating-atopic-dermatitis-in-the-elderly

  • Antimicrobial Peptides Show Promise in Management of Atopic Dermatitis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/antimicrobial-peptides-show-promise-in-management-of-atopic-dermatitis

  • Dupilumab Steadily Reduces IgE Levels of Patients With Atopic Dermatitis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/dupilumab-steadily-reduces-ige-levels-of-patients-with-atopic-dermatitis

  • Roflumilast Cream Meets Primary Endpoint for Treatment of Atopic Dermatitis

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/roflumilast-cream-meets-primary-endpoint-for-treatment-of-atopic-dermatitis

  • Lebrikizumab Receives Positive Opinion for Atopic Dermatitis Treatment in Europe

Pentru detalii, click aici:

https://www.dermatologytimes.com/view/lebrikizumab-receives-positive-opinion-for-atopic-dermatitis-treatment-in-europe

Lectură plăcută!

  • Alte noutăți:

Review of Dermatology Times: ce este nou în acnee? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-acnee/

Review of Dermatology Times: ce este nou în rozacee? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-rozacee/

Review of Dermatology Times: ce este nou în vitiligo? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-vitiligo/

Review of Dermatology Times: ce este nou în alopecii? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-alopecii/

Review of Dermatology Times: ce este nou în medicina estetică? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-medicina-estetica/

Review of Dermatology Times: ce este nou în melasmă? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-melasma/

Review of Dermatology Times: ce este nou în dermatita seboreică? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-dermatita-seboreica/

Review of Dermatology Times: ce este nou în psoriazis? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-psoriazis/

Review of Dermatology Times: ce este nou în hidrosadenita supurativă? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-hidrosadenita-supurativa/

Review of Dermatology Times: ce este nou în prurigo nodularis? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-prurigo-nodularis/

Review of Dermatology Times: ce este nou în tumorile cutanate? – https://e-dermatologie.md/review-of-dermatology-times-ce-este-nou-in-tumorile-cutanate/

distribuie